<DOC>
	<DOC>NCT01880671</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy of a novel therapy for treatment of migraine, pain reduction and relief of associated symptoms during ongoing migraine attacks, and presence of a preventive effect post treatment.</brief_summary>
	<brief_title>Evaluation of a New Treatment for Migraine Attacks</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<criteria>Female or male subjects, in otherwise good health, 20 to 55 years of age Subjects who meet the ICHD2 (2nd Edition of The International Headache Classification) criteria for migraine headache Subjects with a minimum of 1 migraine attack per month Attack duration of 4 to 72 hours Normal attack intensity of at least 4 on a 010 VASscale Completed heart surgery Cardiovascular disease Vascular damage on neck vessels Disease other than migraine of the CSN Severe disease of vital body organs Severe psychiatric disorders More than 6 migraine attacks per month</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>